Literature DB >> 17142107

Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia.

Lucio Gullo1.   

Abstract

BACKGROUND & AIMS: Benign pancreatic hyperenzymemia is a newly identified syndrome that is characterized by a chronic increase of serum pancreatic enzymes in the absence of pancreatic disease. When checked at intervals of months or years, the enzyme levels show considerable variation from one test to another, and enzyme normalization is sometimes seen. The purpose of this study was to determine whether these variations can occur on a day-to-day basis.
METHODS: Forty-two subjects with benign pancreatic hyperenzymemia, 28 men and 14 women, mean age 50 years, range 16-68 years, were studied. In each subject serum amylase, pancreatic isoamylase, and lipase levels were determined once daily on each of 5 consecutive days; in 15 of the 42 subjects studied, serum trypsin level was also measured.
RESULTS: In 8 (19%) of the 42 subjects, the serum enzyme levels were abnormally elevated for all 5 days of the study but showed wide fluctuations. In 33 (78.6%) subjects, the hyperenzymemia showed considerable day-to-day variations that included normalizations. In the remaining subject (2.4%), all enzymes were normal. In most of the subjects with hyperenzymemia, 37 of 41, all enzyme levels were elevated, with lipase, and trypsin when performed, showing the highest values. Of the remaining 4 subjects, in 3 only amylase and pancreatic isoamylase were increased and in 1 only lipase.
CONCLUSIONS: The results show that there are marked day-to-day variations, with frequent normalizations, of serum enzyme levels in subjects with benign pancreatic hyperenzymemia. The reason for these wide day-to-day fluctuations is not known.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142107     DOI: 10.1016/j.cgh.2006.09.035

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  5 in total

1.  Benign pancreatic hyperenzymemia (Gullo syndrome), histamine intolerance, and carbohydrate malabsorption.

Authors:  Wolfgang J Schnedl; Dietmar Enko; Harald Mangge; Michael Schenk; Sonja Lackner; Sandra J Holasek
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

2.  Familial association of benign pancreatic hyperenzymaemia and pancreatic cancer.

Authors:  L Gullo; M Migliori; P Fusaroli; G Caletti
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

3.  Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

Authors:  Claire F Friedman; Varina Clark; Andrew V Raikhel; Tim Barz; Alexander N Shoushtari; Parisa Momtaz; Margaret K Callahan; Jedd D Wolchok; Paul B Chapman; Matthew D Hellmann; Michael A Postow
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 4.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

Review 5.  Significant elevations of serum lipase not caused by pancreatitis: a systematic review.

Authors:  Ahmer M Hameed; Vincent W T Lam; Henry C Pleass
Journal:  HPB (Oxford)       Date:  2014-06-03       Impact factor: 3.647

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.